Clinincal analysis of the leukocytopenia caused by mycophenolate mofetil

Objective To retrospectively analyze the leukocytopenia caused by mycophenolate mofetil (MMF) and summarize the methods of treatment.Methods Twenty five renal transplant recipients who suffered from leukocytopenia caused by MMF were divided into three groups: moderate group, severe group and critical group. The ways of treatment and prognosis were compared among them. Results The incidence of leukocytopenia caused by MMF was 4% (25/632). The effective rate in the severe and critical groups treated with recombinant human granulocyte colony stimulating factor (rhG CSF) was 92%(12/13). To decrease the dosage of MMF could eliminate the risk of severe or critical leukocytopenia.Conclusion The drug suspensory leukocytopenia caused by MMF was not really unfrequent, but it could be treated by rhG CSF effectively. It was important to renal insufficient patients to decrease the dosage of MMF properly.